Dr. Malcolm Mason of Cardiff University in Wales discusses his report that adding radiotherapy to androgen deprivation therapy for locally advanced prostate cancer produced a durable survival benefit compared with hormone therapy alone. Findings come from the final 10-year analysis of a phase III intergroup trial carried out by the U.K. Medical Research Council, the National Cancer Institute of Canada, and the Southwest Oncology Group.